髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展  

Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma

作　　者：滕远 李莉娟[1,2] 张连生[1,2] TENG Yuan;LI Lijuan;ZHANG Liansheng(Second Clinical Medical College of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二临床医学院,甘肃兰州730030 [2]兰州大学第二医院血液科,甘肃兰州730030

出　　处：《陕西医学杂志》2024年第6期858-861,共4页Shaanxi Medical Journal

基　　金：国家自然科学基金资助项目(82360029)。

摘　　要：多发性骨髓瘤(MM)是一种不可治愈的B细胞恶性肿瘤,治疗方案包括化疗和自体干细胞移植。然而,目前药物在控制肿瘤进展和延长MM缓解时间方面作用有限,也并非所有患者都能够接受自体干细胞移植。多结构域B细胞淋巴瘤2(Bcl-2)家族蛋白,特别是髓细胞白血病1(MCL-1)的过度表达在MM的发病机制中起着关键作用。MCL-1过度表达与MM患者耐药和总体不良预后相关。因此,抑制MCL-1蛋白是杀死骨髓瘤细胞的一种治疗策略。在过去的十年中,选择性MCL-1抑制剂的开发取得了显著进展。现对MCL-1抑制剂在MM治疗中的研究进展进行介绍。Multiple myeloma(MM)is an incurable plasma B-cell malignancy.Treatment options include combination chemotherapy and autologous stem cell transplantation.However,the role of current drugs in controlling tumor progression and prolonging remission time of MM is limited,and not all patients are able to receive autologous stem cell transplantation.The overexpression of Bcl-2 family proteins,particularly myeloid cell leukemia 1(MCL-1),plays a critical role in the pathogenesis of MM.The overexpression of MCL-1 is associated with drug resistance and overall poor prognosis in MM patients.Thus,inhibition of MCL-1 protein is a therapeutic strategy to kill myeloma cells.Over the past decade,significant progress has been made in the development of selective MCL-1 inhibitors.This article reviews the research progress of MCL-1 inhibitors in the treatment of MM.

关 键 词：多发性骨髓瘤 髓细胞白血病1抑制剂 B细胞淋巴瘤2 耐药 自体干细胞移植 

分 类 号：R733.3[医药卫生—肿瘤]